News and Publications

NEWS

07/18/2023

Arkuda Therapeutics to Present Update on ARKD-104, its First-in-Class Oral Development Candidate for the Treatment of Frontotemporal Dementia and other Neurodegenerative Disorders at the Alzheimer’s Association International Conference 2023

Study demonstrates ARKD-104 has excellent CNS drug-like properties, increases PGRN in the CNS of non-human primates a…

04/04/2023

Arkuda Therapeutics Strengthens Management Team to Support Ongoing Discovery and Translation to the Clinic

Duane Burnett, PhD, appointed Chief Technology Officer, Raymond Hurst, PhD, promoted to Senior Vice President, Head o…

02/09/2022

Arkuda Therapeutics Raises $64 Million Series B Financing to Advance Pipeline of Programs Targeting Lysosomal Biology to Treat Neurodegenerative Diseases

Funding to support progression of lead progranulin enhancer program into IND-enabling studies Small molecule platform…

PUBLICATIONS

07/18/2023

ARKD-104, A Potential Treatment of Frontotemporal Dementia and Other Neurodegenerative Disorders

Serena Hung, Raymond S. Hurst, Jean-François Blain, Christopher Holler, Angela Chen, Morgan Brand, Anna-Maria Alves,…

10/07/2021

DISCOVERY OF SMALL MOLECULES FOR THE TREATMENT OF PD-GBA

Natasha Khatri, Mary K. Wozniak, Jerusha K. Brendel, Anna-Maria Alves, Christopher J. Holler, James C. Lanter, Duane …

04/08/2020

DISCOVERY OF NOVEL SMALL MOLECULES FOR THE TREATMENT OF FTD-GRN

Christopher J. Holler, Angela Chen, Natasha Khatri, James C. Lanter, Ricardo L. Sanz, Jerusha K. Brendel, Mary Woznia…